Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022
Market Study
Published: May 2012
Pages: 101
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 1699.00 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Medical Devices
Our latest pharma report - Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022 - offers a comprehensive view of the global nuclear medicine imaging systems market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses, revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the nuclear medicine imaging systems market in 2011 to be worth $1.5bn. Growth in this market will be driven by new technology and varied uses of the technology.
Despite experiencing a decline in sales volume and reduced demand in the aftermath of the global economic recession, the nuclear medicine market recovered well, and has seen strong growth in recent years. Much of this growth has been linked to the advent of hybrid units, such as positron emission tomography/computed tomography (PET/CT) scans, where both anatomical and functional images can be captured. For example, the combination of Positron Emission Tomography (PET) with other imaging modalities, such as MRI (Magnetic Resonance Imaging) has allowed for the imaging of cartilage damage, previously thought unreliable.
Nuclear Medicine Imaging Devices: Market Global Market Prospects 2012-2022 report forecasts the size and value of leading national/regional markets including the US, Europe, Japan, India and China. For each of these, visiongain identifies prevailing trends and strategies that will steer this diagnostic technology over the forecast period. Developed nuclear medicine markets such as the US and UK are highly saturated and the focus is likely to be towards upgrading stand-alone PET and SPECT system with fully integrated hybrid units, that offer a high level of anatomical and functional detail. Emerging countries such as China and India will offer more opportunity, due a lack of nuclear medicine facilities and technologies, and increased healthcare spending. It has been predicted that healthcare investment in these countries is expected to double in the next seven years.
How will the nuclear medicine imaging systems market develop this decade? Which regions offer the most significant growth opportunities between 2012 and 2022? Which of the nuclear medicine based imaging devices are growing most strongly? Who are the leading companies in the nuclear medicine imaging systems market? What are some promising technological developments in the market?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Why you should buy Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022
In this report, you will receive the following benefits in particular:
• You will receive our assessment of the current market for nuclear medicine imaging systems, with respect to the leading segments, companies and national markets
• You will discover sales trends for the overall nuclear medicine imaging systems market from 2011 to 2022 - seeing where commercial growth will occur
• You will discover sales trends for the Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) market from 2011 to 2022, with detailed discussions of market potential
• You will receive sales forecasts for leading national/regional markets (US, Europe, Japan, India and China), with informed discussion
• You will assess leading manufacturers and products in the nuclear medicine imaging systems market, with information on the pipeline products
• You will examine the strengths, weaknesses, opportunities and threats (SWOT analysis) facing the nuclear medicine imaging systems market from 2012 onwards
• You will be able to investigate competition and opportunities influencing the nuclear medicine technology from 2012 onwards
• You will see what will stimulate and restrain the market from 2012, with analysis of the recent market trends
• You will discover the unmet needs in the market, driving the growth from 2012 onwards.
Despite experiencing a decline in sales volume and reduced demand in the aftermath of the global economic recession, the nuclear medicine market recovered well, and has seen strong growth in recent years. Much of this growth has been linked to the advent of hybrid units, such as positron emission tomography/computed tomography (PET/CT) scans, where both anatomical and functional images can be captured. For example, the combination of Positron Emission Tomography (PET) with other imaging modalities, such as MRI (Magnetic Resonance Imaging) has allowed for the imaging of cartilage damage, previously thought unreliable.
Nuclear Medicine Imaging Devices: Market Global Market Prospects 2012-2022 report forecasts the size and value of leading national/regional markets including the US, Europe, Japan, India and China. For each of these, visiongain identifies prevailing trends and strategies that will steer this diagnostic technology over the forecast period. Developed nuclear medicine markets such as the US and UK are highly saturated and the focus is likely to be towards upgrading stand-alone PET and SPECT system with fully integrated hybrid units, that offer a high level of anatomical and functional detail. Emerging countries such as China and India will offer more opportunity, due a lack of nuclear medicine facilities and technologies, and increased healthcare spending. It has been predicted that healthcare investment in these countries is expected to double in the next seven years.
How will the nuclear medicine imaging systems market develop this decade? Which regions offer the most significant growth opportunities between 2012 and 2022? Which of the nuclear medicine based imaging devices are growing most strongly? Who are the leading companies in the nuclear medicine imaging systems market? What are some promising technological developments in the market?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Why you should buy Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022
In this report, you will receive the following benefits in particular:
• You will receive our assessment of the current market for nuclear medicine imaging systems, with respect to the leading segments, companies and national markets
• You will discover sales trends for the overall nuclear medicine imaging systems market from 2011 to 2022 - seeing where commercial growth will occur
• You will discover sales trends for the Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) market from 2011 to 2022, with detailed discussions of market potential
• You will receive sales forecasts for leading national/regional markets (US, Europe, Japan, India and China), with informed discussion
• You will assess leading manufacturers and products in the nuclear medicine imaging systems market, with information on the pipeline products
• You will examine the strengths, weaknesses, opportunities and threats (SWOT analysis) facing the nuclear medicine imaging systems market from 2012 onwards
• You will be able to investigate competition and opportunities influencing the nuclear medicine technology from 2012 onwards
• You will see what will stimulate and restrain the market from 2012, with analysis of the recent market trends
• You will discover the unmet needs in the market, driving the growth from 2012 onwards.
Companies Listed
Bracco Diagnostics
Center for Drug Evaluation and Research (CDER)
Coulter Pharma
Covidien
Digirad Corporation
Electron
EUSA Pharma
Food and Drug Administration (FDA)
GE Healthcare
Immunomedics
Molypharma
Neoprobe
Pharmalucence
Philips
Positron Corporation
Shanghai Apex Electronics
Siemens